Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter

Launched by CHILDREN'S CANCER AND LEUKAEMIA GROUP · Jan 26, 2003

Keywords

ClinConnect Summary

OBJECTIVES:

* Compare the response and cure rate of coagulase-negative staphylococcal septicemia in patients receiving chemotherapy through a central venous catheter treated with 2 different schedules of teicoplanin.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and number of central venous catheter lumens (1 vs 2). Patients are randomized to one of two treatment arms.

* Arm I: Patients receive teicoplanin IV bolus every 12 hours for 3 doses and then once daily for 5 doses (total of 7 days).
* Arm II: Patients receive teicopla...

Gender

ALL

Eligibility criteria

• DISEASE CHARACTERISTICS:
• • Suspected septicemia caused by coagulase-negative staphylococci
• • Single or double lumen (no triple lumen) central venous catheter (CVC) (including subcutaneous ports) that can be flushed and aspirated
• • Expected to remain in situ for at least 8 weeks
• • No coagulase-negative septicemia associated with existing CVC within the past 12 weeks
• • Receiving chemotherapy for neoplastic condition, aplastic anemia, Fanconi's anemia, Langerhans' cell histiocytosis, or myelodysplasia
• PATIENT CHARACTERISTICS:
• Age:
• • 2 months and over
• Performance status:
• • Not specified
• Life expectancy:
• • Not specified
• Hematopoietic:
• • Not specified
• Hepatic:
• • Not specified
• Renal:
• • Creatinine clearance at least 60 mL/min
• PRIOR CONCURRENT THERAPY:
• • Biologic therapy
• • Not specified
• • Chemotherapy
• • See Disease Characteristics
• • Endocrine therapy
• • Not specified
• • Radiotherapy
• • Not specified
• • Surgery
• • Not specified